Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC

ONCOLOGY

Volumn 14, Issue 7 SUPPL. 5, 2000, Pages 29-34

  Natale, Ronald B ^a   Socinski, Mark ^b   Sandler, Alan ^c   Israel, Valerie P ^d   Miller, Langdon ^e  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; DRUG DERIVATIVE; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REMISSION; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0034221308     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Vafai D, Israel V, Zaretsky S, et al: Phase I/II trial of combination carboplatin and taxol in non-small-cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 14:352, 1995.
2. Natale RB: Preliminary results of a phase I/ II clinical trial of paclitaxel and carboplatin in non-small-cell lung cancer. Semin Oncol 23(suppl 16):51-54, 1996.
3. Johnson DH: Paclitaxel combination chemotherapy in non-small-cell lung cancer. Lung Cancer 18(Suppl 2):23, 1997.
4. Kelly K, Crowley J, Bunn PA, et al: A randomized phase III trial of paclitaxel plus carboplatin (PC) vs vinorelbine plus cisplatin (VC) in untreated advanced non-small-cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial (abstract). Proc Am Soc Clin Oncol 18:461a, 1999.
5. Natale RB: Taxanes/Platinum - A new standard for NSCLC [discussion]. Presented at non-small-cell lung cancer slide session, 31st Annual Meeting of the American Society of Clinical Oncology, May 23, 1995.
6. Johnson DH, Zhu J, Schiller J, et al: E1594 - a randomized phase III trial in metastatic non-small-cell lung cancer (NSCLC) - outcome of PS 2 patients (Pts): An Eastern Cooperative Group trial (ECOG) (abstract 1779). Proc Am Soc Clin Oncol 18:461a, 1999.
7. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992.
8. Baker L, Khan R, Lynch T, et al: Phase II study of irinotecan (CPT-11) in advanced non-small-cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 16:461a, 1997.
9. Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992.
10. DeVore R, Crawford J, Dimery I, et al: Phase II trial of irinotecan (CPT-11) plus cisplatin (CDDP) in advanced NSCLC (abstract). Proc Am Soc Clin Oncol 16:466a, 1997.
11. Wagner H, Faderl B, Dankelmann E, et al: Phase II study of irinotecan in combination with cisplatin as first-line chemotherapy in advanced non-small cell-lung cancer (NSCLC) (abstract 2032). Proc Am Soc Clin Oncol 18:527a, 1999.